Myosin-XVA Inhibitors

Chemical inhibitors of Myosin-XVA act through various mechanisms to impede its motor activity, which is essential for numerous cellular functions. (±)-Blebbistatin, along with its isomer (-)-Blebbistatin, targets the ATPase domain of Myosin-XVA, blocking ATP hydrolysis, a crucial step for myosin's motor activity. By binding to this domain,(±)-Blebbistatin prevents Myosin-XVA from engaging in the conformational changes needed for force generation and motility. Similarly, 2,3-Butanedione 2-Monoxime (BDM) disrupts Myosin-XVA function by altering the myosin head conformation, consequently impairing ATPase activity and the motor activity of myosin. The inhibition effect of BDM results in a diminished capacity of Myosin-XVA to convert chemical energy into mechanical work.

Other inhibitors, such as ML-7 and ML-9, specifically target myosin light chain kinase, reducing myosin light chain phosphorylation, thereby decreasing Myosin-XVA's actin-based motility. W-7 operates by inhibiting calmodulin, thereby affecting various enzymes and proteins that regulate Myosin-XVA ATPase activity and filament assembly. Furthermore, Y-27632 and H-1152 selectively inhibit Rho kinase, resulting in decreased myosin light chain phosphorylation and subsequent reduction in Myosin-XVA's tension generation. In contrast, SMIFH2 interrupts Myosin-XVA function by suppressing formin homology 2 domains, which are important for actin nucleation and elongation, while CK-636 and CK-548 hinder the Arp2/3 complex, disrupting actin polymerization that supports the structural framework required for Myosin-XVA's motor activity. These diverse inhibitory actions collectively contribute to the modulation of Myosin-XVA's role in cellular processes by directly or indirectly impeding its ability to engage in mechanical work.